|
| |
Cellexus Biosystems appoints Dr Julie Bick as its
US-based Chief Scientific Officer
28th March 2007: Cellexus
Biosystems PLC (CBIO:
PLUS Markets) of Cambridgeshire, United Kingdom, is pleased to announce that it
has appointed Dr Julie Bick as its Chief Scientific Officer. Dr Bick has the
world-wide responsibility for leading the Company’s research and customer
support programmes and will be based in the US from its wholly own subsidiary,
Cellexus
Biosystems Inc..
Dr Bick is a biochemist with considerable expertise in cell culture and has
worked in the areas of protein therapeutics, protein engineering and assay
platform development. In joining the Company, Dr Bick brings to the role, a high
level of experience in protein biochemistry, ranging from the development of
expression and purification methods; the analysis of membrane transport systems
and biosynthetic metabolic pathways of yeast, plants and mammals; and studies of
protein kinases and signal transduction cascades within biological systems. Dr
Bick is also accomplished in gene cloning and expression analysis.
Prior to joining Cellexus Biosystems, Dr Bick was a Senior Scientist (group
leader) at Sanofi-Aventis in New Jersey where she was responsible for
development protein expression systems (bacterial, yeast and mammalian cell
lines), for the large-scale production of pharmaceutically relevant proteins and
the generation of transgenic human tissue culture cells for the analysis of
protein-protein interactions.
Dr Bick has also held research positions at: UT South Western Medical Centre
(Dallas, TX), Syngenta, Torrey Mesa Research Institute (San Diego, CA),
AgBiotech Centre, Rutgers University (NJ), and has a Ph.D from Southampton
University (United Kingdom).
“We are delighted to welcome Dr Bick to the Cellexus Biosystems team” stated Dr
Auton (CEO). “Dr Bick brings a huge amount of expertise to the Company. Her
years of practical experience in cell culture and protein expression, her
breadth of hands-on practical knowledge and her skills in teaching gained in US
academic institutions, will be a highly valuable asset for the Company. Dr Bick
has impressed us with her skills and abilities and we are very pleased that she
will be heading-up our global research efforts and our US-focused support
operations, based from our new subsidiary on the East Coast of the USA”.
ENDS
ABOUT CELLEXUS BIOSYSTEMS PLC
Cellexus Biosystems has developed a range of value-added disposables to help
researchers in the biopharmaceutical industry and academia develop new
biopharmaceutical products from cell lines. Biopharmaceuticals are the new breed
of medicines, generated by culturing cells in bioreactors. These medicines are
often proteins, such as antibodies or can be vaccines. The potential of future
medical treatments offered by stem cell research would also fall within this
category. Sales of biopharmaceuticals reached US$60 billion in 2005 and are
growing at 20% per annum.
The Company has already developed a family of products. Three products have been
developed all based around the core technology - the CellexusBagTM – and are
marketed under the name: CellMaker LiteTM. These products potentially offer
significant technological improvements for cell culture and cell growth in the
developing disposables market.
Unlike competitive products, the CellexusBag products do not need to be stirred,
shaken, rocked or rolled, which means the equipment used to manage the cell
culture process is very simple and inexpensive. A patent application protecting
the Company’s intellectual property was filed in December 2005.
High resolution photographs can be downloaded from:
http://www.cellexusbiosystems.com/index_files/CellexusBiosystemsMediaResources.htm
CELLEXUS BIOSYSTEMS PLC:
Cellexus Biosystems PLC
1010 Cambourne Business Park
Cambourne, Cambridge
CB3 6DP, United Kingdom
Dr Kevin Auton, CEO
Tel: +44 1354 657 407
Fax: +44 870 135 5536
Email: kevin.auton@cellexusbiosystems.com
www.cellexusbiosystems.com
CORPORATE ADVISER:
JM Finn & Co
Salisbury House, London Wall, London EC2M 5TA
Mr Clive Carver
Tel: +44 207 628 9688
Email: clive.carver@jmfinn.com
www.jmfinn.com
MEDIA CONTACT FOR CELLEXUS BIOSYSTEMS PLC
Not This Limited
Tel: +44 1480 352 821
Email: info@notthislimited.co.uk
www.notthislimited.co.uk
| |
|
